Semax

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro and a molecular weight of approximately 813.97 Da. It is a modified analog of the ACTH(4-10) fragment, the portion of adrenocorticotropic hormone responsible for its nootropic and neuroprotective properties, but without any hormonal (steroidogenic) activity. Semax was developed over two decades at the Institute of Molecular Genetics of the Russian Academy of Sciences and has been approved as a prescription nootropic and neuroprotective agent in Russia since 2011.

The primary mechanism of action involves potent upregulation of Brain-Derived Neurotrophic Factor (BDNF) and its receptor TrkB. Studies published in Doklady Biological Sciences and Neuroscience Letters demonstrated that a single intranasal dose of Semax increases BDNF mRNA expression by 3-fold to 8-fold in the hippocampus, frontal cortex, and basal forebrain. This BDNF elevation persists for 24 hours despite the peptide's plasma half-life of only 2-3 minutes, indicating that Semax triggers a sustained transcriptional cascade rather than requiring continuous receptor occupancy.

Semax also modulates the expression of nerve growth factor (NGF) and neurotrophin-3 (NT-3), providing a broad neurotrophic support profile. It influences serotonergic neurotransmission by modulating tryptophan hydroxylase expression, and dopaminergic signaling through effects on tyrosine hydroxylase in the substantia nigra. This dual monoamine modulation contributes to the reported improvements in mood, motivation, focus, and cognitive flexibility observed in clinical settings.

In ischemic stroke research, Semax has shown remarkable neuroprotective effects. A study in rats by Dolotov et al. (published in Neuroscience, 2006) demonstrated a 65% reduction in infarct volume when Semax was administered within 4 hours of middle cerebral artery occlusion. Clinical trials in stroke patients (N=80, published in Zhurnal Nevrologii i Psikhiatrii) showed accelerated neurological recovery and improved cognitive outcomes at 3-month follow-up compared to standard care alone.

Intranasal administration is the standard research route, providing direct nose-to-brain delivery via the olfactory and trigeminal nerve pathways. This bypasses the blood-brain barrier and first-pass hepatic metabolism, achieving detectable CNS concentrations within 2-4 minutes. Bioavailability via the intranasal route is estimated at 60-70%. Typical research protocols use 200-600 mcg per day (divided into 2-3 intranasal doses), with cycle lengths of 10-20 days followed by equal rest periods. Subcutaneous injection is an alternative route studied at similar doses.

Lyophilized Semax should be stored at -20C and is stable for 24+ months. Reconstituted nasal spray solutions should be refrigerated at 2-8C and used within 14-21 days, as the methionine residue at position 1 is susceptible to oxidation. Solutions should remain clear and colorless. For intranasal use, bacteriostatic water or sterile saline (0.9% NaCl) are acceptable reconstitution vehicles. Avoid repeated freeze-thaw cycles.

Gene expression profiling of Semax-treated brain tissue (Agapova et al., Genetics, 2007) revealed modulation of 24 genes involved in immune regulation, vascular function, and neurotransmitter metabolism in the first hour, expanding to over 100 genes at 24 hours. This transcriptomic footprint distinguishes Semax from simple receptor agonists and suggests broad neuroprotective and neurorestorative activity.

The safety profile of Semax is well-established across over 15 years of prescription use in Russia. No dependence, tolerance, or withdrawal effects have been reported. It has no hormonal activity despite its ACTH structural origin. Side effects in clinical trials were limited to occasional mild nasal irritation with intranasal use. No mutagenic, teratogenic, or carcinogenic effects have been identified in preclinical toxicology studies.